A multicentre, retrospective study evaluating immune checkpoint inhibitor associated myocarditis in Chinese cancer patients
Latest Information Update: 23 Jun 2020
At a glance
- Drugs Atezolizumab (Primary) ; Camrelizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Sintilimab (Primary) ; Tislelizumab (Primary) ; Toripalimab (Primary) ; Antineoplastics
- Indications Cancer; Solid tumours
- Focus Adverse reactions
Most Recent Events
- 23 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology